

**LISTING OF THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application.

1-18. (canceled)

19-20. (canceled)

21. (previously presented) A method for the beneficial alteration or maintenance of bone density, or in the prevention or treatment of bone fracture, which comprises administering to a human subject a composition comprising formononetin and one or more of biochanin, genistein, or daidzein in a therapeutically effective ratio of formononetin to said isoflavones of 15:1 to 4:1, optionally in association with one or more carriers, excipients, auxiliaries, and/or diluents.

22-27. (canceled)

28. (currently amended) A method according to claim 21 for the ~~treatment or prevention of osteoporosis~~ beneficial alteration or maintenance of bone density.

29. (previously presented) A method according to claim 21 wherein the ratio of formononetin to said isoflavones is from 15:1 to 5:1.

30. (original) A method according to claim 21 wherein said composition is in the form of a solid dosage form.

31. (currently amended) A method according to claim 24 ~~30~~ wherein said dosage form comprises a tablet, capsule, granular preparation, buccal delivery vehicle or suppository.

32. (original) A method according to claim 21 wherein said formononetin and biochanin comprise an extract of chickpea or clover.

33. (original) A method according to claim 32 wherein said clover is selected from red clover (*T. pratense*), subterranean clover (*T. subterranean*) or white clover (*T. repens*).

34. (original) A method according to claim 33 wherein said clover is red clover.

35. (original) A method according to claim 21 wherein the human subject is a pre-menopausal, menopausal or post-menopausal woman.

36-40. (canceled)

41. (previously presented) A method according to claim 21 for the prevention or treatment of bone fracture.

42. (previously presented) A method according to claim 41 wherein said method is a method of preventing or treating fractures involving bone with predominant cortical bone tissue.

43. (original) A method according to claim 42 wherein said bone is selected from the femoral neck, femur, humerus, radius, ulna or tibia bone.

44-45. (canceled)

46. (new) A method according to claim 28 wherein the bone density in the human subject to be treated is associated with, or is symptomatic of, osteoporosis.